The estimated Net Worth of Julia P Gregory is at least $1.67 Миллион dollars as of 25 October 2022. Ms. Gregory owns over 9,523 units of Biohaven Ltd stock worth over $916,754 and over the last 17 years she sold BHVN stock worth over $0. In addition, she makes $758,183 as Independent Director at Biohaven Ltd.
Sign up
Ms. Gregory BHVN stock SEC Form 4 insiders trading
Julia has made over 6 trades of the Biohaven Ltd stock since 2015, according to the Form 4 filled with the SEC. Most recently she bought 9,523 units of BHVN stock worth $99,992 on 25 October 2022.
The largest trade she's ever made was exercising 28,117 units of Biohaven Ltd stock on 3 October 2022 worth over $89,693. On average, Julia trades about 3,559 units every 116 days since 2008. As of 25 October 2022 she still owns at least 25,665 units of Biohaven Ltd stock.
You can see the complete history of Ms. Gregory stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Julia Gregory biography
Julia Paige Gregory is Independent Director of the Company. Ms. Gregory has served as a director of our Company since August 2017. Ms. Gregory has been Chairman and CEO of Isometry Advisors, Inc., a biotechnology financial, strategy and management advisory firm, since April 2016. Ms. Gregory formerly served as Chief Executive Officer at ContraFect Corporation (NASDAQ: CFRX) from November 2013 through March 2016 and as a member of ContraFect’s Board of Directors from April 2014 through March 2016. Prior to her appointment as CEO, she served as ContraFect’s Executive Vice President and Chief Financial Officer from July 2012 to November 2013. Prior to her time at ContraFect, she served as President and CEO of Five Prime Therapeutics, Inc. (NASDAQ: FPRX) from 2009 until August 2011, and as Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) from 2000 to 2008. Ms. Gregory has twenty years of investment banking experience, starting at Dillon, Read & Co. and subsequently at Punk, Ziegel & Company, where she served as the head of investment banking and head of its life sciences practice. Ms. Gregory has also served on the Board of Directors at The Global TB Alliance for Drug Development, The Institute for the Study of Aging, a private foundation for Alzheimer’s, and Clinipace, Inc., and currently serves on the Boards of Directors of Cavion, Inc., Cell Medica Ltd., IMV, Inc., Iconic Therapeutics, Inc., a private biopharmaceutical company in San Francisco, CA, and the Sosei Group Corporation. Ms. Gregory obtained a Masters of Business Administration from the Wharton School at the University of Pennsylvania, and earned her B.A. at George Washington University.
What is the salary of Julia Gregory?
As the Independent Director of Biohaven Ltd, the total compensation of Julia Gregory at Biohaven Ltd is $758,183. There are 9 executives at Biohaven Ltd getting paid more, with Vlad Coric having the highest compensation of $6,787,630.
How old is Julia Gregory?
Julia Gregory is 67, she's been the Independent Director of Biohaven Ltd since 2017. There are no older and 15 younger executives at Biohaven Ltd.
What's Julia Gregory's mailing address?
Julia's mailing address filed with the SEC is C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, 94158.
Insiders trading at Biohaven Ltd
Over the last 8 years, insiders at Biohaven Ltd have traded over $8,186,598,135 worth of Biohaven Ltd stock and bought 8,852,002 units worth $137,738,037 . The most active insiders traders include Robert J Hugin, John W Childs и Declan Doogan. On average, Biohaven Ltd executives and independent directors trade stock every 14 days with the average trade being worth of $2,840,776. The most recent stock trade was executed by John W Childs on 18 July 2024, trading 28,400 units of BHVN stock currently worth $1,013,028.
What does Biohaven Ltd's logo look like?
Complete history of Ms. Gregory stock trades at ContraFect Corp, Lexicon Pharmaceuticals Inc, Biohaven Ltd и Nurix Therapeutics
Biohaven Ltd executives and stock owners
Biohaven Ltd executives and other stock owners filed with the SEC include:
-
Vlad Coric,
Chief Executive Officer, Director -
William Jones,
Chief Commercial Officer, Migraine and Common Diseases -
Charles Conway,
Chief Scientific Officer -
Kimberly Gentile,
Senior Vice President - Clinical Operations -
James Engelhart,
Chief Financial Officer, Treasurer -
Elyse Stock,
Chief Medical Officer -
John Tilton,
Chief Commercial Officer, Rare and Orphan Diseases -
Dr. Vladimir Coric M.D.,
Chairman, CEO & Pres -
William Jones M.B.A.,
Chief Commercial Officer of Migraine & Common Diseases -
Julia Gregory,
Independent Director -
John Childs,
Director -
Gregory Bailey,
Director -
Dr. Elyse Stock M.D.,
Chief Medical Officer -
Kimberly Gentile,
Sr. VP of Clinical Operations -
Robert Berman,
Lead - Special Projects and Medical Oversight -
Robert Hugin,
Director -
Michael Heffernan,
Director -
Thomas Lynch,
Chairman of the Board -
Clifford Bechtold M.S.,
Pres & GM of Biohaven Ireland and Chief Compliance Officer -
Wendy Goss,
Exec. Admin. Assistant -
Dr. Charles Conway,
Chief Scientific Officer -
George C. Clark,
VP & Chief Accounting Officer -
Matthew DeLawder,
Director of Accounting -
Matthew Buten,
Chief Financial Officer -
Albert Cha,
Director -
Robert Repella,
Director -
Eric Aguiar,
-
Biotech Inc. Portage,
-
Declan Doogan,
-
Irina Antonijevic,
-
Kishan Mehta,
-
George C. Clark,
VP, Chief Accounting Officer -
Matthew Buten,
Chief Financial Officer -
Pharmaceutical Holding Co L...,
-
Bruce Car,
Chief Scientific Officer